Amebiasis (ICD-11: 1A36) - Complete Clinical Coding Guide

1. Introduction

Amebiasis is an intestinal infection caused by the protozoan Entamoeba histolytica, a unicellular parasite that can invade the intestinal mucosa and, in more severe cases, disseminate to other organs, especially the liver. This condition represents an important global public health problem, affecting millions of people annually, particularly in regions with inadequate sanitary conditions and limited access to treated drinking water.

The clinical importance of amebiasis lies not only in its high prevalence in endemic areas, but also in its capacity to cause serious and potentially fatal complications when not diagnosed and treated appropriately. The disease can manifest asymptomatically, as acute amebic colitis, or as amebic liver abscess, the latter being an extraintestinal complication that requires immediate medical attention.

Correct coding of amebiasis is fundamental to various aspects of modern medical practice. It enables appropriate epidemiological tracking of the disease, facilitating the implementation of preventive measures in at-risk areas. Furthermore, it ensures appropriate reimbursement by health services, assures continuity of care among different professionals and institutions, and contributes to research on the efficacy of available treatments. The precise use of the 1A36 ICD-11 code also aids in the differentiation of other intestinal infections by protozoa, avoiding diagnostic confusion that can lead to inappropriate treatments and preventable complications.

2. Correct ICD-11 Code

Code: 1A36

Description: Amebiasis

Parent category: Intestinal infections caused by protozoa

The code 1A36 in the International Classification of Diseases, 11th Revision (ICD-11), specifically designates amebiasis caused by Entamoeba histolytica. This code encompasses all clinical manifestations of amebic infection, including the intestinal form (amebic colitis, amebic dysentery) and extraintestinal forms (amebic liver abscess, cutaneous amebiasis, cerebral amebiasis, among others).

The hierarchical structure of ICD-11 positions this code within the chapter on intestinal infections caused by protozoa, recognizing the parasitic nature of the disease and its primary fecal-oral transmission route. This classification facilitates systematic organization of epidemiological data and allows international comparisons regarding disease incidence and prevalence.

It is important to note that code 1A36 is specific for infections caused by Entamoeba histolytica, the only pathogenic member of the genus Entamoeba that causes invasive disease in humans. Other species of intestinal amoebas, such as Entamoeba dispar and Entamoeba moshkovskii, are morphologically similar but do not cause invasive disease and therefore should not be coded with 1A36.

3. When to Use This Code

The code 1A36 should be used in specific clinical scenarios where there is confirmation or strong clinical suspicion of infection by Entamoeba histolytica. Below, we present detailed practical situations:

Scenario 1: Confirmed acute amebic colitis Patient presents with a history of bloody diarrhea (dysentery) of gradual onset, with intense abdominal cramping and tenesmus. Parasitological stool examination demonstrates the presence of trophozoites or cysts of Entamoeba histolytica, or specific antigen detection testing is positive. Colonoscopy may reveal characteristic "button-hole" shaped ulcers of the disease. In this case, code 1A36 is appropriate, as there is laboratory confirmation of amebic infection with compatible clinical manifestations.

Scenario 2: Amebic liver abscess Patient with high fever, pain in the right hypochondrium, painful hepatomegaly, and compatible epidemiological history (recent travel to endemic area or poor sanitary conditions). Imaging studies (ultrasound or computed tomography) demonstrate single or multiple cystic lesions in the right lobe of the liver. Serology for amebiasis is positive, with elevated titers of anti-E. histolytica antibodies. Even in the absence of current intestinal symptoms, code 1A36 is correct, as amebic liver abscess is an extraintestinal complication of amebiasis.

Scenario 3: Ameboma (inflammatory intestinal mass) Patient with history of previous or current amebic infection presents with a palpable abdominal mass, usually in the ascending colon or cecum. Imaging studies suggest an intestinal tumor-like lesion. Biopsy or surgical findings confirm it to be a granulomatous inflammatory mass caused by E. histolytica, without evidence of malignancy. Code 1A36 is appropriate for this chronic complication of intestinal amebiasis.

Scenario 4: Asymptomatic carrier with detection on screening Asymptomatic individual undergoing routine parasitological stool examination (for example, to obtain a health certificate or preoperative evaluation) presents with a positive result for E. histolytica cysts confirmed by molecular testing or antigen detection tests that differentiate E. histolytica from E. dispar. Even without symptoms, code 1A36 should be used, as the carrier represents a transmission risk and may develop invasive disease in the future.

Scenario 5: Perianal cutaneous amebiasis Patient with active intestinal amebic disease develops painful ulcerated lesions in the perianal or perineal region, resulting from direct extension of intestinal infection. Biopsy of skin lesions demonstrates the presence of trophozoites of E. histolytica. This rare extraintestinal manifestation justifies the use of code 1A36.

Scenario 6: Fulminant amebic colitis Patient with severe presentation of amebic colitis, characterized by profuse bloody diarrhea, intense abdominal pain, abdominal distension, high fever, and signs of systemic toxicity. There is risk of intestinal perforation and peritonitis. Confirmation can be made by parasitological examination or antigen detection, and emergency treatment should be initiated even before definitive laboratory confirmation. Code 1A36 is appropriate for this medical emergency related to amebiasis.

4. When NOT to Use This Code

It is fundamental to recognize situations in which code 1A36 should not be applied, avoiding coding errors that may compromise patient care and the quality of epidemiological data:

Infection by Entamoeba dispar or other non-pathogenic amoebas When parasitological examination identifies amoeba cysts, but specific tests (PCR, antigen detection) confirm that it is Entamoeba dispar, Entamoeba moshkovskii, or other non-invasive commensal species, code 1A36 should not be used. These species do not cause disease and do not require specific treatment, although they may indicate exposure to inadequate sanitary conditions.

Infectious diarrhea from other causes Patients with bloody diarrhea should be carefully evaluated before assigning code 1A36. Other causes of dysentery include bacterial infections (Shigella, Salmonella, Campylobacter, enteroinvasive Escherichia coli), which require different codes and specific treatments. The absence of laboratory confirmation of E. histolytica prevents the use of code 1A36.

Inflammatory bowel disease Conditions such as ulcerative colitis or Crohn's disease may present symptoms similar to amebic colitis, including bloody diarrhea and abdominal cramps. Differentiation is crucial, as treatment with corticosteroids for inflammatory bowel disease may worsen undiagnosed amebiasis. Negative laboratory tests for E. histolytica and histopathological findings characteristic of inflammatory bowel disease exclude the use of code 1A36.

Hepatic abscesses of other etiologies Bacterial pyogenic hepatic abscesses, fungal abscesses, or parasitic cystic lesions (such as echinococcosis) may mimic amebic hepatic abscess on imaging studies. Negative serology for amebiasis, positive bacterial cultures, or other specific findings indicate that code 1A36 is not appropriate.

Intestinal neoplasms Intestinal masses that may initially be confused with ameboma should be carefully investigated. Histopathological confirmation of malignant neoplasia (colorectal adenocarcinoma, lymphoma) excludes the diagnosis of amebiasis and requires appropriate oncological coding.

5. Step-by-Step Coding Process

Step 1: Assess diagnostic criteria

The diagnosis of amebiasis requires a combination of clinical, epidemiological, and laboratory findings. First, evaluate the clinical presentation: gradual diarrhea with or without blood, abdominal cramping, tenesmus, low-grade or absent fever in the intestinal form; high fever, right upper quadrant pain, and hepatomegaly in the hepatic abscess form.

Investigate the epidemiological history: exposure to poor sanitary conditions, consumption of contaminated water or food, travel to endemic areas, contact with carriers. These factors significantly increase the pretest probability.

Essential diagnostic tools include: parasitological stool examination (ideally three samples on alternate days), specific antigen detection tests for E. histolytica in stool, PCR for molecular differentiation between species, serology (ELISA for anti-E. histolytica IgG antibodies), colonoscopy with biopsy when indicated, and imaging studies (ultrasound or computed tomography) for suspected extraintestinal complications.

Laboratory confirmation is preferable before definitive coding, although in urgent situations with high clinical suspicion, treatment and provisional coding may be initiated.

Step 2: Check specifiers

ICD-11 allows the addition of specifiers to detail the presentation of amebiasis. Consider documenting:

Location: Intestinal (amebic colitis, amebic dysentery) versus extraintestinal (hepatic abscess, cutaneous amebiasis, cerebral amebiasis, pulmonary amebiasis).

Severity: Mild (diarrhea without significant dehydration), moderate (diarrhea with dehydration or moderate bleeding), severe (fulminant colitis, intestinal perforation, complicated hepatic abscess).

Duration: Acute (symptoms lasting less than four weeks), chronic (persistent or recurrent symptoms lasting more than four weeks).

Complications: Presence of toxic megacolon, intestinal perforation, peritonitis, hepatic abscess rupture, dissemination to other organs.

Treatment status: First episode, recurrence, treatment failure, asymptomatic carrier.

These specifiers, although they do not change the main code 1A36, should be clearly documented in the medical record to guide treatment and prognosis.

Step 3: Differentiate from other codes

1A30: Infections caused by Balantidium coli This infection is caused by a ciliated protozoan, not an ameba. Clinically, it can cause similar diarrhea, but microscopic identification is distinctive: Balantidium coli is much larger than E. histolytica and presents characteristic cilia. The epidemiological history often includes contact with pigs. Use 1A30 only when B. coli is specifically identified.

1A31: Giardiasis Caused by Giardia lamblia (also called G. intestinalis or G. duodenalis), this infection typically causes watery diarrhea, steatorrhea, abdominal distension, and excessive flatulence, but rarely bloody diarrhea. The trophozoites and cysts of Giardia have completely different morphology from E. histolytica. There is no invasion of the intestinal mucosa or extraintestinal complications such as hepatic abscess. Use 1A31 when Giardia is identified.

1A32: Cryptosporidiosis Infection caused by Cryptosporidium spp., characterized by profuse watery diarrhea, especially in immunocompromised patients. Identification requires special techniques (modified acid-fast staining or immunofluorescence). It does not cause deep intestinal ulcers or hepatic abscess. Use 1A32 when Cryptosporidium oocysts are identified.

Practical differentiation: The key to correct coding lies in the specific laboratory identification of the etiological agent. Molecular tests and specific antigen detection are increasingly available and eliminate diagnostic ambiguities.

Step 4: Required documentation

To ensure appropriate coding and continuity of care, medical documentation should include:

Mandatory checklist:

Detailed description of symptoms (type of diarrhea, presence of blood or mucus, frequency, duration)
Vital signs and physical examination findings (temperature, blood pressure, signs of dehydration, abdominal pain on palpation, hepatomegaly)
Epidemiological history (travel, exposure to suspicious water or food, known cases of contact)
Results of specific laboratory tests (stool parasitology, antigen detection, serology, PCR)
Imaging study findings when performed (ultrasound, computed tomography, colonoscopy)
Definitive diagnosis: "Intestinal amebiasis confirmed by E. histolytica detection" or "Amebic hepatic abscess confirmed by positive serology"
ICD-11 code: 1A36
Therapeutic plan (specific medications, duration of treatment, follow-up)
Guidance on transmission prevention and hygiene measures

This complete documentation not only justifies the coding but also facilitates communication between healthcare professionals and institutions.

6. Complete Practical Example

Clinical Case

A 42-year-old male patient, a farmer, seeks medical care with a complaint of diarrhea for 12 days. He reports that initially he presented with liquid stools without blood, 4-5 times per day, associated with mild abdominal cramping. Over the last five days, he noticed the presence of blood and mucus in his stools, with increased bowel movement frequency (8-10 times per day) and intensification of abdominal cramping. He also reports tenesmus and a sensation of incomplete evacuation. He denies fever but reports general malaise and loss of appetite.

In the epidemiological history, the patient mentions that he works in a rural area with basic sanitary conditions, consumes untreated well water, and had recent contact with other workers who presented with similar symptoms a few weeks ago.

On physical examination, he appears in fair general condition, hydrated, afebrile (axillary temperature of 36.8°C), blood pressure of 120/80 mmHg, heart rate of 88 bpm. The abdomen is slightly distended, with increased bowel sounds, diffusely tender on palpation, especially in the lower quadrants, without signs of peritoneal irritation. There is no palpable hepatomegaly.

Evaluation performed:

Laboratory tests were requested including complete blood count (which showed mild leukocytosis with 11,500 leukocytes/mm³ and mild anemia with hemoglobin of 11.2 g/dL), parasitological stool examination in three consecutive samples, and antigen detection test for E. histolytica in stool.

The parasitological stool examination revealed the presence of hemophagous trophozoites of Entamoeba histolytica in the second sample. The specific antigen detection test was positive, confirming E. histolytica and not commensal species such as E. dispar.

Diagnostic reasoning:

The clinical presentation of progressive diarrhea evolving to dysentery (bloody diarrhea with mucus), associated with abdominal cramping and tenesmus, is highly suggestive of invasive infectious colitis. The epidemiological history of exposure to untreated water in a rural area and contact with other suspected cases significantly increase the probability of parasitic infection.

Laboratory confirmation through the identification of hemophagous trophozoites of E. histolytica on parasitological examination and the positivity of the specific antigen test definitively establish the diagnosis of intestinal amebiasis (amebic colitis).

Other differential diagnoses were excluded: invasive bacterial infections (absence of high fever and significant leukocytosis), inflammatory bowel disease (acute history without previous symptoms, parasitological confirmation), and other intestinal parasitoses (specific identification of the etiological agent).

Justification for coding:

The diagnosis of amebic colitis was confirmed by clinical, epidemiological, and laboratory criteria, fully meeting the requirements for use of code 1A36.

Step-by-Step Coding

Analysis of criteria:

Clinical criteria present: dysentery, abdominal cramping, tenesmus, gradual evolution
Epidemiological criteria present: exposure to untreated water, rural area, contact with suspected cases
Laboratory criteria present: identification of E. histolytica trophozoites, positive antigen test
Absence of exclusion criteria: no evidence of other infections, no prior inflammatory bowel disease

Code chosen: 1A36 - Amebiasis

Complete justification: Code 1A36 is appropriate because the patient presents with definitive laboratory confirmation of Entamoeba histolytica infection through two independent methods (direct microscopy and specific antigen detection), associated with characteristic clinical manifestations of amebic colitis (dysentery, abdominal cramping, tenesmus) and compatible epidemiological context.

Applicable complementary codes:

Code for dehydration may be added if present (5C70)
Code for anemia may be added if clinically significant (3A00)
Document environmental risk factors related (extension codes for social determinants)

Documented therapeutic plan: Treatment with metronidazole was prescribed for the invasive phase, followed by paromomycin for elimination of luminal cysts, with guidance on hydration, hygiene measures, and transmission prevention. Outpatient follow-up scheduled for clinical reevaluation and confirmation of parasitological cure.

7. Related Codes and Differentiation

Within the Same Category

1A30: Infections by Balantidium coli

When to use 1A30 vs. 1A36: Use 1A30 when parasitological examination specifically identifies Balantidium coli, a large ciliated protozoan that causes diarrhea, usually in individuals with contact with pigs. Use 1A36 when Entamoeba histolytica is identified.

Main difference: Balantidium coli is the only pathogenic ciliated protozoan for humans, easily distinguishable microscopically by the presence of cilia and much larger size (50-200 μm) compared to E. histolytica trophozoites (12-60 μm). The clinical presentation may be similar, but B. coli rarely causes extraintestinal complications such as hepatic abscess, which are characteristics of amebiasis.

1A31: Giardiasis

When to use 1A31 vs. 1A36: Use 1A31 when Giardia lamblia is identified in stool through microscopy, antigen detection, or PCR. Use 1A36 exclusively for infections by E. histolytica.

Main difference: Giardiasis typically causes watery diarrhea, steatorrhea (fatty and foul-smelling stools), abdominal distension, and excessive flatulence, but rarely causes bloody diarrhea. Giardia colonizes the small intestine (duodenum and jejunum) without invading the mucosa, whereas E. histolytica invades the colon mucosa causing deep ulcers. Giardiasis does not cause extraintestinal complications such as hepatic abscess. Microscopically, Giardia trophozoites have a characteristic "pear" shape with two nuclei, completely different from E. histolytica.

1A32: Cryptosporidiosis

When to use 1A32 vs. 1A36: Use 1A32 when oocysts of Cryptosporidium spp. are identified through modified acid-fast staining, immunofluorescence, or PCR. Use 1A36 for infections by E. histolytica.

Main difference: Cryptosporidiosis causes profuse self-limited watery diarrhea in immunocompetent individuals, but can be severe and chronic in immunosuppressed patients (especially those with AIDS). Cryptosporidium is an intracellular parasite that infects intestinal epithelial cells without causing deep mucosal invasion or characteristic ulcers. There is no typical bloody diarrhea or extraintestinal complications such as hepatic abscess. Cryptosporidium oocysts (4-6 μm) are much smaller than E. histolytica cysts and require special staining techniques for identification.

Differential Diagnoses

Shigellosis (1A03): Bloody diarrhea caused by bacteria of the genus Shigella. It differs from amebiasis by more acute presentation, higher fever more common, significant leukocytosis, and bacterial identification in stool culture. Amebiasis has a more gradual course and low-grade or absent fever.

Ulcerative colitis (DD50.0): Chronic inflammatory bowel disease that can mimic amebic colitis. It differs by history of recurrent symptoms, specific colonoscopic findings (continuous inflammation starting in the rectum), characteristic histopathology without parasite identification, and response to immunosuppressive treatment.

Colorectal adenocarcinoma (2B90): Can present with rectal bleeding and altered bowel habits. It differs by more advanced typical age, absence of profuse diarrhea, identification of tumor mass on imaging and colonoscopy, and histopathological confirmation of malignancy.

8. Differences with ICD-10

Equivalent ICD-10 code: In ICD-10, amebiasis is coded as A06, with subcategories:

A06.0: Acute amebic dysentery
A06.1: Chronic intestinal amebiasis
A06.2: Nondysenteric amebic colitis
A06.3: Intestinal ameboma
A06.4: Amebic liver abscess
A06.5: Amebic lung abscess
A06.6: Amebic brain abscess
A06.7: Cutaneous amebiasis
A06.8: Amebic infection of other sites
A06.9: Amebiasis, unspecified

Main changes in ICD-11: ICD-11 simplifies the coding of amebiasis by using a single code (1A36) with the possibility of adding extension specifiers to detail the location and severity, rather than multiple subcodes. This approach reflects the modern understanding that amebiasis is a single disease with multiple possible clinical manifestations, all caused by the same etiologic agent.

The ICD-11 structure also facilitates digital coding and interoperability between health information systems, allowing greater flexibility in documenting complications and comorbidities through standardized extension codes.

Practical impact of these changes: For healthcare professionals, the transition to ICD-11 simplifies the process of coding amebiasis, eliminating the need to memorize multiple subcodes. A single code (1A36) is sufficient, with additional specifiers documented in the free text of the medical record or through standardized extension codes.

For epidemiological surveillance systems, the change may require adjustments in data collection systems to ensure that information about the specific location of infection (intestinal vs. extraintestinal) continues to be captured appropriately. However, ICD-11's more flexible structure may facilitate more sophisticated analyses of amebiasis complications and outcomes.

For reimbursement and billing purposes, healthcare institutions will need to update their systems to recognize the new code 1A36 and establish appropriate mappings with ICD-10 codes A06.x during the transition period.

9. Frequently Asked Questions

How is amebiasis diagnosed?

The diagnosis of amebiasis combines clinical evaluation, epidemiological history, and laboratory confirmation. Clinically, intestinal amebiasis is suspected in patients with gradually progressive diarrhea, especially when it progresses to dysentery (diarrhea with blood and mucus), accompanied by abdominal cramps and tenesmus. Laboratory confirmation is essential and can be performed through parasitological examination of stool (ideally three samples on alternate days) to identify trophozoites or cysts of E. histolytica, specific antigen detection tests in stool (which differentiate E. histolytica from non-pathogenic species), or PCR for molecular identification. For amebic liver abscess, serology (detection of anti-E. histolytica IgG antibodies) is highly sensitive and specific, associated with imaging studies (ultrasound or computed tomography) that show characteristic cystic lesions in the liver. Colonoscopy with biopsy may be necessary in cases of difficult diagnosis or to exclude other conditions.

Is treatment available in public health systems?

The medications used in the treatment of amebiasis, especially metronidazole and other nitroimidazoles, are widely available in public health systems in many countries, as they are considered essential medicines by the World Health Organization. The treatment of amebiasis generally involves two phases: a phase with tissue amebicide medication (such as metronidazole or tinidazole) to eliminate invasive trophozoites in tissues, followed by a luminal amebicide (such as paromomycin or iodoquinol) to eliminate cysts in the intestinal lumen and prevent recurrences. In cases of uncomplicated amebic liver abscess, medication treatment alone is generally sufficient, without the need for surgical drainage. Specific availability and prescription protocols vary among different health systems and geographic regions.

How long does amebiasis treatment last?

The duration of amebiasis treatment varies according to the clinical presentation and medications used. For amebic colitis, typical treatment with metronidazole lasts 7-10 days, followed by paromomycin for 7 days to eliminate luminal cysts. For amebic liver abscess, metronidazole is generally administered for 10 days, also followed by luminal amebicide. Tinidazole, when available, may offer shorter regimens (3-5 days) with better tolerability. It is essential to complete the entire course of treatment, including the luminal cyst elimination phase, even after symptom resolution, to prevent recurrences and transmission. Follow-up with control parasitological examinations is recommended 2-4 weeks after treatment completion to confirm parasitological cure.

Can this code be used in medical certificates?

Yes, code 1A36 can and should be used in medical certificates when appropriate, especially in occupational contexts where precise documentation of diagnosis is necessary. Amebiasis, particularly in its more severe forms (amebic colitis with dehydration, liver abscess), justifies temporary leave from work activities during treatment. For food handlers, leave is particularly important to prevent transmission, and return to work should be conditional on confirmation of parasitological cure. In medical certificates, in addition to ICD-11 code 1A36, it is appropriate to include a brief description of the condition (for example, "Intestinal amebiasis under treatment") and the recommended period of leave. Medical confidentiality must be respected, providing only the information necessary to justify the leave without exposing unnecessary clinical details.

Can amebiasis recur after treatment?

Yes, amebiasis can recur after treatment, especially if the initial treatment was incomplete (did not include luminal cyst elimination phase), if there was therapeutic failure (drug resistance, although rare), or if there was reinfection from new exposure to E. histolytica cysts. Recurrence from incomplete treatment is the most common cause and can be prevented by ensuring that the patient completes the entire therapeutic regimen, including the luminal amebicide. Reinfection is possible in individuals who continue to be exposed to inadequate sanitary conditions or contaminated water, highlighting the importance of sustained preventive measures. Patients with a history of amebiasis should be counseled about rigorous personal hygiene, consumption of treated water, and safe food. In cases of recurrence, it is important to confirm the diagnosis again and consider alternative causes before restarting treatment.

Should asymptomatic carriers of amebiasis be treated?

Yes, asymptomatic carriers of Entamoeba histolytica should be treated, even in the absence of symptoms. The main reason is that asymptomatic carriers shed cysts in their feces and represent a source of transmission to other people, especially in environments with inadequate sanitary conditions. Furthermore, asymptomatic carriers may develop invasive disease in the future, especially if there is immunosuppression or other risk factors. Treatment of asymptomatic carriers generally involves only luminal amebicide (such as paromomycin) to eliminate cysts, without the need for tissue amebicide. It is important to differentiate carriers of E. histolytica (pathogenic) from carriers of E. dispar (non-pathogenic), as only the former require treatment. This differentiation requires specific antigen detection tests or PCR, as the two species are morphologically identical under the microscope.

What is the difference between amebiasis and "free-living amoeba"?

Amebiasis (code 1A36) refers specifically to infection by Entamoeba histolytica, an obligate intestinal parasite transmitted via the fecal-oral route through cysts present in contaminated water or food. "Free-living amoebas" are completely different organisms, mainly from the genera Naegleria, Acanthamoeba, and Balamuthia, which live freely in the environment (soil, freshwater) and can cause serious infections of the central nervous system (meningoencephalitis) or ocular infections (keratitis), but do not cause intestinal disease. Infections by free-living amoebas are acquired through exposure to contaminated water (swimming in lakes, use of contact lenses with non-sterile water) and not via the fecal-oral route. These infections have different ICD-11 codes and require completely different treatment. It is important not to confuse intestinal amebiasis (1A36) with infections by free-living amoebas, as they are completely different clinical, epidemiological, and therapeutic conditions.

Can pregnant women have amebiasis and how should it be treated?

Yes, pregnant women can develop amebiasis, and the disease can be particularly concerning during pregnancy due to immunological changes and therapeutic limitations. Diagnosis follows the same principles, with laboratory confirmation whenever possible. Treatment of amebiasis in pregnancy requires special considerations: metronidazole, although widely used, should be avoided in the first trimester when possible due to theoretical concerns about teratogenicity, although human data are reassuring. Paromomycin, a non-absorbed luminal amebicide, is considered safe throughout pregnancy and can be used for mild cases or asymptomatic carriers. For severe cases of amebic colitis or life-threatening liver abscess, treatment with metronidazole should be instituted regardless of gestational trimester, as the benefits outweigh potential risks. Management should be individualized with careful assessment of risks and benefits, preferably with consultation with specialists in infectious diseases and high-risk obstetrics.

Conclusion:

Correct coding of amebiasis using ICD-11 code 1A36 is fundamental for appropriate clinical management, effective epidemiological surveillance, and appropriate allocation of public health resources. This guide provides the necessary tools to identify situations where this code should be applied, differentiate it from other intestinal protozoan infections, and properly document the diagnosis. Specific laboratory confirmation of Entamoeba histolytica, combined with compatible clinical presentation and appropriate epidemiological context, are the cornerstones for correct use of this code. With the transition from ICD-10 to ICD-11, the simplification of the coding structure facilitates the work of health professionals while maintaining the diagnostic accuracy necessary for quality care.

External References

This article was prepared based on reliable scientific sources:

References verified on 2026-02-04

Amebiasis

Share